Q4 2024 Nyxoah SA Earnings Call Transcript
Key Points
- Nyxoah SA (NYXH) is well-positioned to bring its Genio system to the US market by the end of March 2025, with FDA approval expected soon.
- The DREAM study demonstrated strong efficacy for the Genio system, with a 63.5% AHI responder rate and a 71.3% ODI responder rate.
- Genio is the only therapy with clinical evidence proving its efficacy irrespective of a patient's sleeping position, a critical differentiator.
- The company has built a strong US-based team, including key hires in finance, medical, and commercial roles, to support the US launch.
- Nyxoah SA (NYXH) has identified an established CPT code (64568) for reimbursement, aligning with existing HGNS technology pricing.
- The deferred revenue recognition for disposable patches may impact short-term financial results, with EUR600,000 deferred in Q4 2024.
- Operating loss increased to EUR18.3 million in Q4 2024, driven by R&D spending and US commercial investments.
- There is investor concern that the reimbursement level associated with the CPT code 64568 may not be attractive enough for physicians.
- The company faces challenges in ensuring sufficient manufacturing and inventory to meet demand upon US launch.
- There is uncertainty regarding the timing of commercial payer adoption and the potential hurdles in the reimbursement pathway.
Hello, and welcome to Nyxoah fourth quarter 2024 earnings conference call. (Operator Instructions) I would now like to turn the conference over to John Landry. You may begin.
Thank you. Good morning, everyone, and I welcome you to our earnings call for the fourth quarter and full year 2024. Participating from the company today will be Olivier Taelman, Chief Executive Officer; and myself, John Landry, Chief Financial Officer.
During the call, we will discuss our operating activities and review our fourth quarter and full year 2024 financial results released before US market opening today. After which, we will host a question-and-answer session.
The press release can be found on the investor relations section of our website. This call is being recorded and will be archived in the events section on the investor relations tab of our website.
Before we begin, I would like to remind you that any statements that relate to expectations or predictions of future events, market trends, results
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
